DMD Simcyp

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hiroi, T.
Right arrow Articles by Funae, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hiroi, T.
Right arrow Articles by Funae, Y.

Vol. 30, Issue 9, 970-976, September 2002

Catalytic Specificity of CYP2D Isoforms in Rat and Human

Toyoko Hiroi, Toshio Chow, Susumu Imaoka, and Yoshihiko Funae

Department of Chemical Biology, Osaka City University Medical School, Osaka, Japan

In rats, six cytochrome P450 (P450) 2D isoforms have been genetically identified. Nonetheless, there is little evidence of catalytic properties of each CYP2D isoform. In this study, using recombinant CYP2D isoforms (rat CYP2D1, CYP2D2, CYP2D3, and CYP2D4 and human CYP2D6) or hepatic microsomes, we investigated the catalytic specificity toward bufuralol, debrisoquine, and propranolol, which are frequently used as CYP2D substrates. Bufuralol was oxidized to three metabolites by rat and human hepatic microsomes. 1'-Hydroxybufuralol was the major metabolite. 1'2'-Ethenylbufuralol, one of the others, was identified as a novel metabolite. The formation of 1'-hydroxybufuralol and 1'2'-ethenylbufuralol in hepatic microsomes was inhibited by anti-CYP2D antibody, suggesting that these metabolites were formed by CYP2D isoforms. All rat and human recombinant CYP2D isoforms possessed activity for the 1'-hydroxylation of bufuralol, indicating that this catalytic property was common to all CYP2D isoforms. However, the 1'2'-ethenylation of bufuralol was catalyzed only by rat CYP2D4 and human CYP2D6. Debrisoquine was oxidized to two metabolites, 3-hydroxydebrisoquine, and 4-hydroxydebrisoquine, by hepatic microsomes. Recombinant CYP2D2 and CYP2D6 had very high levels of activity for the 4-hydroxylation of debrisoquine with low Km values. Only CYP2D1 had a higher level of 3-hydroxylation than 4-hydroxylation activity. Propranolol 4-hydroxylation was catalyzed by CYP2D2, CYP2D4, and CYP2D6. The 7-hydroxylation of propranolol was catalyzed only by CYP2D2. In conclusion, in rats, bufuralol 1'2'-ethenylation activity was specific to CYP2D4 and debrisoquine 4-hydroxylation and propranolol 7-hydroxylation activities were specific to CYP2D2. These catalytic activities are useful as a probe for rat CYP2D isoforms.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
P. Rowland, F. E. Blaney, M. G. Smyth, J. J. Jones, V. R. Leydon, A. K. Oxbrow, C. J. Lewis, M. G. Tennant, S. Modi, D. S. Eggleston, et al.
Crystal Structure of Human Cytochrome P450 2D6
J. Biol. Chem., March 17, 2006; 281(11): 7614 - 7622.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
N. Sakai, K. Saito, H.-S. Kim, A. Kazusaka, M. Ishizuka, Y. Funae, and S. Fujita
IMPORTANCE OF CYP2D3 IN POLYMORPHISM OF DIAZEPAM P-HYDROXYLATION IN RATS
Drug Metab. Dispos., November 1, 2005; 33(11): 1657 - 1660.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
K. Saito, N. Sakai, H.-S. Kim, M. Ishizuka, A. Kazusaka, and S. Fujita
STRAIN DIFFERENCES IN DIAZEPAM METABOLISM AT ITS THREE METABOLIC SITES IN SPRAGUE-DAWLEY, BROWN NORWAY, DARK AGOUTI, AND WISTAR STRAIN RATS
Drug Metab. Dispos., September 1, 2004; 32(9): 959 - 965.
[Abstract] [Full Text] [PDF]


Home page
Drug Metab. Dispos.Home page
R. S. Foti and M. B. Fisher
IMPACT OF INCUBATION CONDITIONS ON BUFURALOL HUMAN CLEARANCE PREDICTIONS: ENZYME LABILITY AND NONSPECIFIC BINDING
Drug Metab. Dispos., March 1, 2004; 32(3): 295 - 304.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
W. Kishimoto, T. Hiroi, M. Shiraishi, M. Osada, S. Imaoka, S. Kominami, T. Igarashi, and Y. Funae
Cytochrome P450 2D Catalyze Steroid 21-Hydroxylation in the Brain
Endocrinology, February 1, 2004; 145(2): 699 - 705.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.